Li Lizhuo, Bao Yijun, He Songbai, Wang Gang, Guan Yanlei, Ma Dexuan, Wu Rile, Wang Pengfei, Huang Xiaolong, Tao Shanwei, Liu Qiwen, Wang Yunjie, Yang Jingyun
From the Department of Critical Care and Emergency Medicine, The Affiliated Hospital of Hainan Medical University, Haikou, Hainan (LL); Emergency Department, Shengjing Hospital of China Medical University (LL, SH, GW, QL); Department of Neurosurgery, The First Hospital of China Medical University, Shenyang, Liaoning (YB, YG, PW, XH, ST, YW); Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai (DM); Department of Occupational and Environmental Health, School of Public Health, Shenyang Medical College, Shenyang, Liaoning, China (RW); Rush Alzheimer's Disease Center (JY); and Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois (JY).
Medicine (Baltimore). 2015 Nov;94(46):e2028. doi: 10.1097/MD.0000000000002028.
Traumatic brain injury (TBI) is a leading cause of death and disability. Previous studies have investigated the association of apolipoprotein E (APOE) ε4 with functional outcome after TBI and reported inconsistent results.The purpose of this study was to perform a systematic literature search and conduct meta-analyses to examine whether APOE ε4 is associated with poorer functional outcome in patients with TBI.We performed a systematic literature search in PubMed, Cochrane Library, Embase, Google Scholar, and HuGE.The eligibility criteria of this study included the following: Patients had TBI; the studies reported APOE genotype data or provided odds ratios (ORs) and the corresponding 95% confidence intervals (CIs); the functional outcome was assessed using the Glasgow Outcome Scale (GOS) or the Glasgow Outcome Scale Extended (GOSE); and patients were followed for at least 3 months after TBI.In all meta-analyses, we used random-effects models to calculate the odds ratio as a measure of association. We examined the association of APOE ε4 with functional outcome at different time points after TBI.A total of 12 studies met the eligibility criteria and were included in the meta-analyses. We did not find a significant association between APOE ε4 and functional outcome at 6 (P = 0.23), 12 (P = 0.44), and 24 months (P = 0.85) after TBI. However, APOE ε4 was associated with an increased risk of unfavorable long-term (≥6 months) functional outcome after TBI (OR = 1.36, 95% CI: 1.07-1.74, P = 0.01).Limitations of this study include The sample size was limited; the initial severity of TBI varied within and across studies; we could not control for potential confounding factors, such as age at injury and sex; a meta-analysis of the genotype dosage effect was not feasible; and we could not examine the association with specific factors such as neurobehavioral or specific cognitive functions.Our meta-analysis indicates APOE ε4 is associated with the long-term functional outcome of patients with TBI. Future studies that control for confounding factors, with large sample sizes and more homogeneous initial TBI severity levels, are needed to validate the findings from this study.
创伤性脑损伤(TBI)是死亡和残疾的主要原因。以往的研究调查了载脂蛋白E(APOE)ε4与TBI后功能结局的相关性,但报告的结果并不一致。本研究的目的是进行系统的文献检索并开展荟萃分析,以检验APOE ε4是否与TBI患者较差的功能结局相关。我们在PubMed、Cochrane图书馆、Embase、谷歌学术和HuGE中进行了系统的文献检索。本研究的纳入标准如下:患者患有TBI;研究报告了APOE基因型数据或提供了比值比(OR)及相应的95%置信区间(CI);使用格拉斯哥预后量表(GOS)或格拉斯哥扩展预后量表(GOSE)评估功能结局;患者在TBI后至少随访3个月。在所有荟萃分析中,我们使用随机效应模型计算比值比作为关联度的衡量指标。我们研究了TBI后不同时间点APOE ε4与功能结局的相关性。共有12项研究符合纳入标准并被纳入荟萃分析。我们未发现TBI后6个月(P = 0.23)、12个月(P = 0.44)和24个月(P = 0.85)时APOE ε4与功能结局之间存在显著关联。然而,APOE ε4与TBI后长期(≥6个月)功能结局不良风险增加相关(OR = 1.36,95%CI:1.07 - 1.74,P = 0.01)。本研究的局限性包括样本量有限;TBI的初始严重程度在研究内部和研究之间存在差异;我们无法控制潜在的混杂因素,如受伤时的年龄和性别;对基因型剂量效应进行荟萃分析不可行;并且我们无法研究与神经行为或特定认知功能等特定因素的关联。我们的荟萃分析表明,APOE ε4与TBI患者的长期功能结局相关。未来需要开展控制混杂因素、样本量大且初始TBI严重程度水平更均匀的研究,以验证本研究的结果。